

## RESEARCH ARTICLE

# Cytotoxicity Assessments of *Portulaca oleracea* and *Petroselinum sativum* Seed Extracts on Human Hepatocellular Carcinoma Cells (HepG2)

Nida Nayyar Farshori<sup>1</sup>, Ebtesam Saad Al-Sheddi<sup>1</sup>, Mai Mohammad Al-Oqail<sup>1</sup>, Javed Musarrat<sup>2,3</sup>, Abdulaziz Ali Al-Khedhairi<sup>2,3</sup>, Maqsood Ahmed Siddiqui<sup>2,3\*</sup>

### Abstract

The Pharmacological potential, such as antioxidant, anti-inflammatory, and antibacterial activities of *Portulaca oleracea* (PO) and *Petroselinum sativum* (PS) extracts are well known. However, the preventive properties against hepatocellular carcinoma cells have not been explored so far. Therefore, the present investigation was designed to study the anticancer activity of seed extracts of PO and PS on the human hepatocellular carcinoma cells (HepG2). The HepG2 cells were exposed with 5-500 µg/ml of PO and PS for 24 h. After the exposure, cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) assay, neutral red uptake (NRU) assay, and cellular morphology by phase contrast inverted microscope were studied. The results showed that PO and PS extracts significantly reduced the cell viability of HepG2 in a concentration dependent manner. The cell viability was recorded to be 67%, 31%, 21%, and 17% at 50, 100, 250, and 500 µg/ml of PO, respectively by MTT assay and 91%, 62%, 27%, and 18% at 50, 100, 250, and 500 µg/ml of PO, respectively by NRU assay. PS exposed HepG2 cells with 100 µg/ml and higher concentrations were also found to be cytotoxic. The decrease in the cell viability at 100, 250, and 500 µg/ml of PS was recorded as 70%, 33%, and 15% by MTT assay and 63%, 29%, and 17%, respectively by NRU assay. Results also showed that PO and PS exposed cells reduced the normal morphology and adhesion capacity of HepG2 cells. HepG2 cells exposed with 50 µg/ml and higher concentrations of PO and PS lost their typical morphology, become smaller in size, and appeared in rounded bodies. Our results demonstrated preliminary screening of anticancer activity of *Portulaca oleracea* and *Petroselinum sativum* extracts against HepG2 cells, which can be further used for the development of a potential therapeutic anticancer agent.

**Keywords:** HepG2 cells - cytotoxicity - cellular morphology - anticancer activity

*Asian Pac J Cancer Prev*, 15 (16), 6633-6638

### Introduction

Hepatocellular carcinoma, is the sixth most common cancer worldwide, continues to have high prevalence in many Asian countries (Fazeli et al., 2013). Due to the poor prognosis, hepatocellular carcinoma is the fourth fatal cancer in the world (Mohamad et al., 2013). It is also the third most frequent cause of cancer deaths among men worldwide (Parkin et al., 2005). Usually, males are more affected than females and, are most common between the 30-50 years of age (Kumar et al., 2003). Chemotherapy is the most common treatment for the cancer. Unfortunately, many of the chemotherapeutic drugs are non-specific and cause severe side effects. Therefore, searching for new alternative strategies for the treatment and prevention of hepatocellular carcinoma is necessary. Natural products have been considered as a valuable source for the anticancer drug discovery (Svejda et al., 2010; Khan et al., 2011; Randhawa and Alghamdi, 2011; Sharma et al.,

2011; Thoppil et al., 2013; Al-Oqail et al., 2013; Farshori et al., 2013; Al-Sheddi et al., 2014).

*Portulaca oleracea* (purslane), is an annual green herbaceous medicinal plant widespread in temperate and tropical regions of the world (Yang et al., 2009). The pharmacological potential of the *Portulaca oleracea*, such as anti-inflammatory (Chan et al., 2000), antioxidative (Dkhil et al., 2011), anti-bacterial (Zhang et al., 2002), skeletal muscle relaxant (Parry et al., 1993), wound-healing (Rashed et al., 2003), and *in vitro* anti-tumor (Yoon et al., 1999) activities have been reported. The *Petroselinum sativum* (PS) or parsley, a member of the family of Umbelliferae, has also been reported to have antioxidant (Kreydiyyeh et al., 2001; Ahmed et al., 2010), antidiabetic (Yanardag et al., 2003), anti-inflammatory, antiedema antihypertensive, antimicrobial (Wahba et al., 2010) activities. Recently we have also reported that seed and oil extracts of *Petroselinum sativum* induced cytotoxicity against human breast cancer cells (Farshori

<sup>1</sup>Department of Pharmacognosy, College of Pharmacy, <sup>2</sup>Department of Zoology, College of Science, <sup>3</sup>Al-Jeraisy Chair for DNA Research, King Saud University, Riyadh, Saudi Arabia \*For correspondence: [maqsoodahmads@gmail.com](mailto:maqsoodahmads@gmail.com)

Due to the diverse pharmacological and preventive properties of these plant extracts, present investigation was carried out to screen the anticancer activity of seed extracts of *Petroselinum sativum* and *Portulaca oleracea* against hepatocarcinoma cells (HepG2). The HepG2 cell line has been well established *in vitro* model for anti hepatocellular carcinoma (Li et al., 2014).

## Materials and Methods

### Chemicals and consumables

Dulbecco's Modified Eagle's Medium (DMEM) culture medium, antibiotics-antimycotic solution, fetal bovine serum (FBS) and trypsin were purchased from Invitrogen, Life Sciences, USA. Consumables and culture wares used in the study were procured from Nunc, Denmark. All other specified reagents and solvents were purchased from Sigma Chemical Company Pvt. Ltd. St. Louis, MO, USA.

### Plant material and extractions

The seeds of *Portulaca oleracea* and *Petroselinum sativum* and used in this study were obtained from the local market of Riyadh, Saudi Arabia. The seeds were screened manually to remove bad ones. For the preparation of alcoholic extract, the seeds were macerated in alcohol and then filtered. The procedure was repeated several times. The solvent was then evaporated using a rotary evaporator and the residue so obtained was called as the alcoholic extract.

### Cell culture

HepG2, human hepatocellular carcinoma cells were cultured in DMEM, supplemented with 10% FBS, 0.2% sodium bicarbonate and antibiotic/antimycotic solution (100x, 1ml/100 ml of medium). Cells were grown in 5% CO<sub>2</sub> at 37°C in high humid atmosphere. Before the experiments, viability of cells was assessed following the protocol of (Siddiqui et al., 2008). HepG2 cells showing more than 98% cell viability and passage number between 20 and 22 were used in the present study.

### Experimental design

HepG2 cells were exposed to various concentrations (5-500 µg/ml) of seed extracts of *Portulaca oleracea* and *Petroselinum sativum* for a period of 24 h. Following the exposures, HepG2 cells were subjected to assess the cytotoxic responses using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-biphenyl tetrazolium bromide (MTT), neutral red uptake (NRU) assay, and cellular morphology by phase contrast inverted microscope.

### Drug solutions

The *Portulaca oleracea* and *Petroselinum sativum* extracts were not completely soluble in aqueous medium, therefore the stock solutions of all the extracts were prepared in dimethylsulphoxide (DMSO) and diluted in culture medium to reach the desired concentrations. The concentration of DMSO in culture medium was not more than 0.1% and this medium was used as control.

### Cytotoxicity screening

**MTT assay:** Cell viability was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay as described (Siddiqui et al., 2008). Briefly, HepG2 cells (1x10<sup>4</sup>) were allowed to adhere for 24 h CO<sub>2</sub> incubator at 37°C in 96 well culture plates. After the respective exposure, MTT (5 mg/ml of stock in PBS) was added (10 µl/well in 100 µl of cell suspension), and plates were incubated for 4 h. Then, supernatants were discarded and 200 µl of DMSO were added to each well and mixed gently. The developed color was read at 550 nm using multiwell microplate reader (Thermo Scientific, USA). Untreated sets were also run under identical conditions and served as control.

### Neutral red uptake (NRU) assay

Neutral red uptake (NRU) assay was carried out following the protocol (Siddiqui et al., 2010). Briefly, after the exposure, the medium was aspirated and cells were washed twice with PBS, and incubated for 3 h in a medium supplemented with neutral red (50 µg/ml). Medium was washed off rapidly with a solution containing 0.5% formaldehyde and 1% calcium chloride. Cells were subjected to further incubation of 20 min at 37°C in a mixture of acetic acid (1%) and ethanol (50%) to extract the dye. The plates were read at 540 nm using multiwell microplate reader (Thermo Scientific, USA). The values were compared with the control sets run under identical conditions.

### Morphological analysis

Morphological changes in HepG2 cells exposed to increasing concentrations (5-500 µg/ml) of PO and PS extracts were taken using an inverted phase contrast microscope (OLYMPUS CKX 41) at 20 X magnification.

### Statistical analysis

The results were expressed as mean and standard error of means (SEM). One way ANOVA was employed to detect differences between the groups of treated and control. The values showing p<0.05 were considered as statistically significant.

## Results

### Cytotoxicity assessments by MTT and NRU assay

The cytotoxicity assessments by MTT and NRU assay in HepG2 cells exposed to PO extract are summarized in Figure 1 and 2. HepG2 cells were exposed to various concentrations (5-500 µg/ml) of PO for 24 h. Results showed that PO induced statistically significant (p<0.001) decrease in the cell viability of HepG2 cells in a concentration dependent manner. The HepG2 cells exposed to PO at 50 µg/ml and higher concentrations were found to be cytotoxic. The cell viability was recorded as 67%, 31%, 21%, and 17% at 50, 100, 250, and 500 µg/ml of PO, respectively by MTT assay (Figure 1) and 91%, 62%, 27%, and 18% at 50, 100, 250, and 500 µg/ml of PO, respectively by NRU assay (Figure 2).


HepG2 cells exposed to PS extract at various concentrations (5-500 µg/ml) for 24 h also exhibit the

statistically significant ( $p < 0.001$ ) decrease in the cell viability in a concentration dependent manner (Figure 4 and 5). PS exposed HepG2 cells with 100  $\mu\text{g/ml}$  and higher concentrations decreased the cell viability. The decrease in the cell viability at 100, 250, and 500  $\mu\text{g/ml}$  of PS was recorded as 70%, 33%, and 15% by MTT assay (Figure 4) and 63%, 29%, and 17% by NRU assay (Figure 5), respectively. The PO and PS at 25  $\mu\text{g/ml}$  and


lower concentrations did not show any decrease in the cell viability of HepG2 cells as observed by MTT and NRU assays. The PO extract was found to be more cytotoxic to HepG2 cells as compared to PS extract.

#### Morphological changes


The morphological changes observed in HepG2 cells are shown in Figures 3 and 6. Alterations in the morphology of HepG2 cells exposed to PO and PS were found in a concentration dependent manner. Cells exposed to 50  $\mu\text{g/ml}$  and higher concentrations of PO for 24 h lose the normal morphology and cell adhesion capacity of




**Figure 1. Cytotoxicity Assessment by MTT Assay in HepG2 Cells following the Exposure of Various Concentrations of *Portulaca oleracea* (PO) seed Extracts for 24 h.** Values are mean $\pm$ SE of three independent experiments. \* $p < 0.05$ , \*\* $p < 0.01$  vs control




**Figure 2. Cytotoxicity Assessment by NRU Assay in HepG2 cells Following the Exposure of Various Concentrations of *Portulaca oleracea* (PO) seed Extracts for 24 h.** Values are mean $\pm$ SE of three independent experiments. \* $p < 0.05$ , \*\* $p < 0.01$  vs control




**Figure 4. Cytotoxicity Assessment by MTT Assay in HepG2 Cells Following the Exposure of various Concentrations of *Petroselinum sativa* (PS) seed Extracts for 24 h.** Values are mean $\pm$ SE of three independent experiments. \* $p < 0.05$ , \*\* $p < 0.01$  vs control



**Figure 5. Cytotoxicity Assessment by NRU Assay in HepG2 Cells Following the Exposure of various Concentrations of *Petroselinum sativa* (PS) seed Extracts for 24 h.** Values are mean $\pm$ SE of three independent experiments. \* $p < 0.05$ , \*\* $p < 0.01$  vs control



**Figure 3. Morphological Changes in HepG2 Cells Following the exposure of Various Concentrations of *Portulaca oleracea* (PO) Seed Extracts for 24 h.** Images were taken using an inverted phase contrast microscope (OLYMPUS CKX 41) at 20 X magnification



**Figure 6. Morphological Changes in HepG2 Cells following the Exposure of Various Concentrations of Petroselinum Sativa (PS) Seed Extracts for 24 h.** Images were taken using an inverted phase contrast microscope (OLYMPUS CKX 41) at 20 X magnification

HepG2 cells as compared to control (Figure 3). However, PS at 100 µg/ml and higher concentrations lose the normal morphology and cell adhesion capacity of HepG2 cells as compared to control. Most of cells at higher concentrations appeared rounded in the shape (Figure 6). The PO and PS at 25 µg/ml and lower concentration did not effect on the morphology of HepG2 cells.

## Discussion

Several studies demonstrate that traditional medicine could be a promising source in the development of a potential therapeutic anticancer drug (Pan and Ho, 2008; Al-Oqail et al., 2013; Farshori et al., 2013, Al-Sheddi et al., 2014). Herbal medicines have long been viewed as a source of curative remedy based on religious and cultural traditions (Ghazanfer, 1994; Pal and Shukla, 2003; Saetung et al., 2005). *Portulaca oleracea* (purslane), is well known for its preventive and pharmacological potential, such as anti-inflammatory (Chan et al., 2000), antioxidative (Dkhil et al., 2011; Erkan et al., 2012), anti-bacterial (Zhang et al., 2002) activities. Thus, in order to provide comparative data on *in vitro* anticancer activity of the extracts of *Portulaca oleracea* (PO) and *Petroselinum sativum* (PS) on human hepatocellular carcinoma cell lines (HepG2), the present study was designed. The cytotoxicity of PO and PS extracts were observed by MTT and NRU assays. The results indicated that PO and PS seed extracts decreased the cell viability of HepG2 cells in a concentration-dependent manner. The study demonstrated that 50–500 µg/ml of PO and 100–500 of PS concentrations significantly ( $p < 0.01$ ) decreased the cell viability. Our results are in accordance with the previous studies showing *in vitro* anticancer activity of PO at 50–500 µg/ml concentrations against the human cervical cancer (HeLa) and the mouse cervical carcinoma (U14) cells (Zhao et al., 2013). The protective potential of PO against Ehrlich ascites carcinoma bearing albino mice have also been reported (Ali et al., 2014). Our results from present study suggest that the cytotoxicity of the PO might be due to free radical scavenging property of extract in the presence of antioxidant phytochemicals (Han et al., 2003; Peksel et al., 2006; Ebrahimzadeh et al., 2009) and the presence of active compounds (Huang and Zou, 2011; Kma, 2013), which is showing anticancer activity

on HepG2 cells. Studies also showed that constitutes of various plant extracts also inhibit the growth of other cancerous cells (Li et al., 1995; Kim et al., 2002; Kumi-Diaka and Butler, 2000). Recently, we have also shown that plant extracts decreased the cell viability of various cancer cells, including human epidermoid cancer cells (HEp2), human breast adenocarcinoma cells (MCF-7), human amniotic epithelial cells (WISH), and human lung cancer cells (Al-Oqail et al., 2013, Farshori et al., 2013, Al-Sheddi et al., 2014). The alterations in the morphology of HepG2 exposed to various concentrations of seed extracts of PO and PS observed by phase contrast inverted microscope showed the detachment of the cells with the increasing concentrations. These kinds of alterations in the cellular morphology induced by plant extracts at higher concentration have also been reported (Berrington and Lall, 2012; Al-Oqail et al., 2013, Farshori et al., 2013, Al-Sheddi et al., 2014).

Our results also showed that PS extract significantly decreased the cell viability of HepG2 in a concentration dependent manner. The antioxidant (Kreydiyyeh et al., 2001; Ahmed et al., 2010), antidiabetic (Yanardag et al., 2003), anti-inflammatory, antiedema antihypertensive, and antimicrobial (Wahba et al., 2010) activities of PS extracts have previously been reported. Our results are in well correspondence with the previous findings of anticancer activity of seed extract of PS against MCF-7 cells (Farshori et al., 2013). Many studies have also shown that this kind of effects towards cancerous cells may be due to the presence of bioactive components such as, polysaccharides, flavonoids, coumarins, monoterpene glycoside and alkaloids in these plant extracts (Xiang et al., 2005, Xin et al., 2008, Li et al., 2009, Tan et al., 2013). Various plant extracts have also been found to induce cytotoxicity on human breast cancer T47D cells (Abdolmohammadi et al., 2008), human gastric adenocarcinoma (MK-1), human uterus carcinoma (HeLa), and murine melanoma (B16F10) cells (Fujika et al., 1999). Recently, we have also shown that PS seed extracts decreased the cell viability of human breast cancer cells (MCF-7) (Farshori et al., 2013). The PO extract showed higher cytotoxicity in HepG2 cells as compared to the PS extract. The difference in the response of plant extracts towards the HepG2 cells could be due to the presence of active components (Samarakoon et al., 2010)



and flavanoids (Das et al., 2010).

In conclusion, our results showed that *Portulaca oleracea* (PO) and *Petroselinum sativum* (PS) extracts significantly reduced the cell viability, and altered the cellular morphology of HepG2 cells in a concentration dependent manner. The data also revealed that HepG2 cells were more sensitive to PO than the PS extract. Further molecular studies are undergoing to elucidate the mechanism(s) of action of these extracts on human hepatocellular carcinoma cells.

## Acknowledgements

This project was supported by NSTIP strategic technologies programs, number (12-MED2491-02) in the Kingdom of Saudi Arabia.

## References

- Abdolmohammadi MH, Fouladdel Sh, Shafiee A, et al (2008). Anticancer effects and cell cycle analysis on human breast cancer T47D cells treated with extracts of *Astrodaucus persicus* (Boiss.) Drude in comparison to doxorubicin. *DARU*, **16**, 2.
- Ahmed NZ, El-Deib KM, Ahmed MM (2010). Studies on curcuma longa, chicorium intybus and *Petroselinum sativum* water extracts against cisplatin-induced toxicity in rats. *J Am Sci*, **6**, 545-58.
- Al-Oqail MM, Farshori NN, Al-Sheddi ES, et al (2013). *In vitro* cytotoxic activity of seed oil of fenugreek against various cancer cell lines. *Asian Pac J Cancer Prev*, **14**, 1829-32.
- Al-Sheddi ES, Farshori NN, Al-Oqail MM, et al (2014). Cytotoxicity of nigella sativa seed oil and extract against human lung cancer cell line. *Asian Pac J Cancer Prev*, **15**, 983-7.
- Ali HA, Hussein MA, Mohammed WE (2014). Comparative effects of purslane seed oil (PSO) and 5-Flourourasil on ehrlich ascites carcinoma (EAC) in female albino mice. *Int J Pharma Sci*, **4**, 424-30.
- Berrington D, Lall N (2012). Anticancer activity of certain herbs and spices on the cervical epithelial carcinoma (HeLa) cell line. *Evid-Based Compl Alter Med*, **2012**, 1-11.
- Chan K, Islam MW, Kamil M, et al (2000). The analgesic and anti-inflammatory effects of *Portulaca oleracea* L. subsp. sativa (Haw.) Celak *J Ethnopharmacol*, **73**, 445-51.
- Das A, Banik NL, Ray SK (2010). Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. *Cancer*, **116**, 164-76.
- Dkhil MA, Abdel Moniem A, Al-Quraishy S, et al (2011). Antioxidant effect of purslane (*Portulaca oleracea*) and its mechanism of action. *J Med Plant Research*, **5**, 1589-93.
- Ebrahimzadeh MA, Nabavi SF, Nabavi SM (2009). Essential oil composition and antioxidant activity of *Pterocarya fraxinifolia*. *Pak J Biol Sci*, **12**, 957-63.
- Erkan N (2012). Antioxidant activity and phenolic compounds of fractions from *Portulaca oleracea* L. *Food Chem*, **133**, 775-81.
- Farshori NN, Al-Sheddi ES, Al-Oqail MM, et al (2013). Anticancer activity of *Petroselinum sativum* seed extracts on MCF-7 human breast cancer cells. *Asian Pac J Cancer Prev*, **14**, 5719-23.
- Fazeli Z, Pourhoseingholi MA, Vahedi M, Zali MR (2012). Burden of hepatocellular carcinoma in Asia. *Asian Pac J Cancer Prev*, **13**, 5955-8.
- Fujika T, Furumi K, Fujii H, et al (1999). Antiproliferative constituents from umbelliferae plants. A new furanocoumarin and falcariindiol furanocoumarin ethers from the root of angelica japonica. *Chem Pharm Bull*, **47**, 96-100.
- Ghazanfer SA (1994). Handbook of Arabian Medicinal Plants. CRC Press, Boca Raton, FL p. 180.
- Han SH, Yang BS, Kim HJ (2003). Effectiveness of aromatherapy massage on abdominal obesity among middle aged women. *J Korean Acad Nurs*, **33**, 839-46.
- Huang W, Zou K (2011). Cytotoxicity of a plant steroidal saponin on human lung cancer cells. *Asian Pac J Cancer Prev*, **12**, 513-7.
- Khan MA, Chen HC, Tania M, et al (2011). Anticancer activities of Nigella sativa (Black Cumin). *Afr J Tradit Compl Alter Med*, **8**, 226-32.
- Kim YJ, Liu RH, Rychlik JL, et al (2002). The enrichment of a ruminal bacterium (*Megasphaera elsdenii* YJ-4) that produces the trans-10, cis-12 isomer of conjugated linoleic acid. *J Appl Microbiol*, **92**, 976-82.
- Kma L (2013). Roles of plant extracts and constituents in cervical cancer therapy. *Asian Pacific J Cancer Prev*, **14**, 3429-36.
- Kreydiyyeh SI, Usta J, Kaouk I, et al (2001). The mechanism underlying the laxative properties of parsley extract. *Phytomedicine*, **8**, 382-8.
- Kumar V, Fausto N, Abbas A (editors) (2003). Robbins & Cotran pathologic basis of disease (7<sup>th</sup> ed). *Saunders*. pp. 914-7.
- Kumi-Diaka J, Butler A (2000). Caspase-3 protease activation during the process of genistein induced apoptosis in TM4 cells. *Biol Cell*, **92**, 115-24.
- Li PG, Cao NX, Jiang RT, et al (2014). Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells. *Asian Pac J Cancer Prev*, **15**, 2753-8.
- Li YZ, Li CJ, Pinto AV, et al (1995). Release of mitochondria cytochrome C in both apoptosis and necrosis-induced by beta-lapachone in human carcinoma cells. *Mol Med*, **5**, 232-9.
- Li, F, Li Q, Gao D, et al. (2009). Preparation and antidiabetic activity of polysaccharide from *Portulaca oleracea* L. *Afr J Biotech*, **8**, 569-73.
- Mohamad AP, Fazeli Z, Ashtari S, Fatemeh SFB (2013). Mortality trends of gastrointestinal cancers in Iranian population. *Gastroenterol Hepatol Bed to Bench*, **6**.
- Pal SK, Shukla Y (2003). Herbal medicine: current status and the future. *Asian Pacific J Cancer Prev*, **4**, 281-8.
- Pan MH, Ho CT (2008). Chemopreventive effects of natural dietary compounds on cancer development. *Chem Soc Rev*, **37**, 2558-74.
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. *CA Cancer J Clin*, **55**, 74-108.
- Parry O, Marks JA, Okwuasaba FK (1993). The skeletal muscle relaxant action of *Portulaca oleracea*: role of potassium ions. *J Ethnopharmacol*, **40**, 187-94.
- Peksel A, Arisan I, Yanardag (2006). Antioxidant activities of aqueous extracts of purslane (*Portulaca oleracea* Subsp. Sativa L). *Ital J Food Sci*, **3**, 295-308.
- Randhawa MA, Alghamdi MS (2011). Anticancer activity of *Nigella sativa* (Black Seed) - a review. *Am J Chinese Med*, **39**, 1075-91.
- Rashed AN, Afifi FU, Disi AM (2003). Simple evaluation of the wound healing activity of a crude extract of *Portulaca oleracea* L. (growing in Jordan) in Mus musculus JVI-1. *J Ethnopharmacol*, **88**, 131-6.
- Saetung A, Itharat A, Dechsukum C, et al (2005). Cytotoxic activity of Thai medicinal plants for cancer treatment. *Songklanakarin J Sci Technol*, **27**, 469-78.
- Samarakoon SR, Thabrew I, Galhena PB, et al (2010). A comparison of the cytotoxic potential of standardized

- aqueous and ethanolic extracts of a polyherbal mixture comprised of *Nigella sativa* (seeds), *Hemidesmus indicus* (roots) and *Smilax glabra* (rhizome). *Pharmacogn Res*, **2**, 335-42.
- Sharma JVC, Pitchaiah G, Satyavati D, et al (2011). *In vitro* Anticancer activity of methanolic extract of roots of *Glochidion zeylanicum* (Gaertn). *IJRPBS*, **2**, 760-4.
- Siddiqui MA, Kashyap MP, Kumar V, et al (2010). Protective potential of trans-resveratrol against 4-hydroxynonenal induced damage in PC12 cells. *Toxicol In vitro*, **24**, 1592-8.
- Siddiqui MA, Singh G, Kashyap MP, et al (2008). Influence of cytotoxic doses of 4-hydroxynonenal on selected neurotransmitter receptors in PC-12 cells. *Toxicol In vitro*, **22**, 1681-8.
- Svejda B, Aguiriano-Moser V, Sturm S, et al (2010). Anticancer activity of novel plant extracts from *Trailliaedoxa gracilis* (W. W. Smith & Forrest) in human carcinoid KRJ-I cells. *Anticancer Res*, **30**, 55-64.
- Tan GCS, Wong KM, Pearle-Wong GQ, et al (2013). *In vitro* Cytotoxic and antiproliferative effects of *Portulaca oleracea* methanol extract on breast, cervical, colon and nasopharyngeal cancerous cell lines. *Sains Malaysiana*, **42**, 927-35.
- Thoppil RJ, Harlev E, Mandal A, Nevo E, Bishayee A (2010). Antitumor activities of extracts from selected desert plants against HepG2 human hepatocellular carcinoma cells. *Pharm Biol*, **51**, 668-74.
- Wahba NM, Ahmed AS, Ebraheim ZZ (2010). Antimicrobial effects of pepper, parsley, and dill and their roles in the microbiological quality enhancement of traditional Egyptian Kareish cheese. *Foodborne Pathog Dis*, **7**, 411-8.
- Xiang L, Xing D, Wang W, et al (2005). Alkaloids from *Portulaca oleracea* L. *Phytochemistry*, **66**, 2595-601.
- Xin hL, Xu YF, Yue XQ, et al (2008). Analysis of chemical constituents in extract from *Portulaca oleracea* L. with GC-MS method. *Pharma J Chin People's Liberat Army*, **24**, 133-6.
- Yanardag R, Bolkent S, Tabakoglu-Oguz A, et al (2003). Effects of Petroselinum crispum extract on pancreatic B cells and blood glucose of streptozotocin-induced diabetic rats. *Biol Pharm Bull*, **26**, 1206-10.
- Yang ZJ, Liu CJ, Xiang L, Zheng YN (2009). Phenolic alkaloids as a new class of antioxidants in *Portulaca oleracea*. *Phytother Res*, **23**, 1032-5.
- Yoon JW, Ham SS, Jun HS (1999). *Portulaca oleracea* and tumor cell growth. US Patent. 5869060. Washington DC: Patent and Trademark Office.
- Zhang XJ, Ji YB, Qu ZY, Xia JC, Wang L (2002). Experimental studies on antibiotic functions of *Portulaca oleracea* L. *in vitro*. *Chin J Microbiol Immunol*, **14**, 277-80.
- Zhao R, Gao X, Cai Y, et al (2013). Antitumor activity of *Portulaca oleracea* L. polysaccharides against cervical carcinoma *in vitro* and *in vivo*. *Carbohydrate Polymers*, **96**, 376-83.